2型糖尿病大鼠胃肠手术模型的建立

中国临床药理学与治疗学 ›› 2012, Vol. 17 ›› Issue (8): 888-891.

2型糖尿病大鼠胃肠手术模型的建立

夏亚斌, 郑成竹

第二军医大学附属长海医院微创外科,上海 200433

收稿日期:2012-03-19 修回日期:2012-04-19 出版日期:2012-08-26 发布日期:2012-08-14
通讯作者: 郑成竹,男,本科,教授,研究方向:胃肠外科。Tel: 13901663698 E-mail: fredzhengzz@hotmail.com
作者简介:夏亚斌,男,硕士,副教授,研究方向:胃肠外科。Tel: 18605531143 E-mail: 77278431@qq.com

Establishments of the gastrointestinal surgery model in type 2 diabetes mellitus rats

XIA Ya-bin, ZHENG Cheng-zhu

Minimally Invasive Surgery Center, Changhai Hospital, the Second Military Medical University, Shanghai 200433, China

Received:2012-03-19 Revised:2012-04-19 Online:2012-08-26 Published:2012-08-14

摘要/Abstract

摘要： 目的: 利用糖尿病大鼠建立手术治疗糖尿病的实验动物模型。方法: SPF级SD大鼠60只,所有动物给予8周的高脂高糖饮食,随后予以腹腔注射链脲佐菌素 (40 mg/kg)制备糖尿病大鼠模型。造模成功一周后行手术,选取24只随机分为2组,分别为十二指肠空肠旁路手术组(DJB,n=12)、Roux-en-y旁路手术组(RYGB,n=12)。结果: 术后大鼠的总生存率达到83.3%,术后第8周,两组大鼠均存活10只。结论: 胃肠道手术的2型糖尿病大鼠模型是可行的,可用于长期观察及检测研究,有助于临床评估相关手术的远期效果。

关键词: 胃肠手术, 2型糖尿病, 十二指肠空肠旁路, Roux-en-y旁路

Abstract: AIM: To establish the gastrointestinal surgery model in type 2 diabetes mellitus rats.METHODS: 60 SPF-class male Sprague-Dawley(SD) rats were used. The rats were given a high-fat-sugar diet for 8 wk, followed with an intraperitoneal injection of streptozotocin (40mg/kg). 1 week after get success model, 24 rats from success model were randomly divided into two groups : duodenal jejunal bypass group(DJB, n=12),Roux-en-Y gastric bypass group(RYGB, n=12).RESULTS: 8 weeks after surgery,surviving rats in each group were ten, the overall survival rate of rats reached 83.3%.CONCLUSION: The animal model of type 2 diabetes to be given gastrointestinal operation as the treatment is feasible,which means can be used in long-term observation of foundation research and evaluation the effectiveness of clinical work.

Key words: Gastrointestinal surgery, Type 2 diabetes mellitus, Duodenal jejuna bypass, Roux-en-Y gastric bypass

中图分类号:

R965.2

夏亚斌, 郑成竹. 2型糖尿病大鼠胃肠手术模型的建立[J]. 中国临床药理学与治疗学, 2012, 17(8): 888-891.

XIA Ya-bin, ZHENG Cheng-zhu. Establishments of the gastrointestinal surgery model in type 2 diabetes mellitus rats[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(8): 888-891.

参考文献

[1] 何银辉, 徐海燕, 孙霞,等.2型糖尿病合理用药策略[J]. 中国临床药理学与治疗学, 2011, 27(7): 837-840.
[2] Rubino F,R'bibo SL,del Genio F,et al. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus[J]. Nat Rev Endocrinol,2010,6(2):102-109.
[3] Adams TD,Gress RE,Smith SC,et al. Long-term mortality after gastric bypass surgery[J]. N Engl J Med,2007,357(8):753-761.
[4] Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis[J].JAMA,2004,292(14):1724-1737.
[5] Buchwald H, Estok R, Fahrbach K, et al. Trends in mortality in bariatric surgery: a systematic review and meta-analysis[J]. Surgery,2007,142(4): 621-632.
[6] Sjöström L,Lindroos AK,Peltonen M,et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery[J].N Engl J Med, 2004, 351(26): 2683- 2693.
[7] Sjöström L,Gummesson A,Sjöström CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial[J]. Lancet Oncol,2009,10(7):653-662.
[8] Srinivasan K,Viswanad B,Asrat L,et al. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and Pharmacological screening[J].. Pharmacol Res,2005,52(4):313-320.
[9] 郭啸华,刘志红,李恒等.实验性2型糖尿病大鼠模型的建立[J].肾脏病与透析肾移植杂志,2000,9(4):351-355.
[10] Han LO, Zhou LH, Cheng SJ, et al.Key details of the duodenal-jejunal bypass in type 2 diabetes mellitus rats[J].World J Gastroenterol,2011,17(45): 5021-5027.
[11] Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease[J]. Ann Surg, 2004, 239(l):l-11.
[12] Rubino F, Forgione A, Cummings DE,et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes[J]. Ann Surg,2006,244(5):741-749.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[3]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[4]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[5]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[6]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[7]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[8]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[9]	曾晓凡, 许宜琪, 刘书, 吴茜, 李自保, 何俊俊, 金岳龙, 赵永莉, 何春玲, 高家林. 回顾性分析小剂量阿司匹林对2型糖尿病病人非致死性心梗和脑梗一级预防的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 665-671.
[10]	邵茜, 郁亚南, 黄钰涵, 王晓彤, 凌宏威, 吕冬梅, 王涛. 艾塞那肽降低2型糖尿病患者体重的预测因素研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 287-294.
[11]	代红雨, 杨坤, 胡如春, 周红梅, 马佩敏, 郝倩. 0.25%罗哌卡因用于糖尿病患者坐骨神经阻滞的时效研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1278-1284.
[12]	陈倩, 王亚峰, 朵德龙, 常亚娥, 严英俊, 段坤坤. 琥珀酸曲格列汀对2型糖尿病小鼠肠道菌群的改变[J]. 中国临床药理学与治疗学, 2022, 27(1): 15-24.
[13]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[14]	徐永霞, 谢明珠, 宫牧雪, 黄嘉莹, 赵丽, 朱德发. 25羟维生素D对老年2型糖尿病患者胰岛β细胞功能的影响[J]. 中国临床药理学与治疗学, 2020, 25(9): 1021-1026.
[15]	赵海玲, 张浩军, 赵婷婷, 严美花, 董晞, 马亮, 李平. PNPLA2基因多态性与中国汉族2型糖尿病患者缺血性脑卒中的相关性研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 664-669.